- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04316845
18F-fluorocholine PET/CT for Hyperparathyroidism
18F-Fluorocholine PET/CT in the Pre-operative Localization of Hyperfunctional Parathyroid Gland in Primary and Secondary Hyperparathyroidism
Hyperparathyroidism is a common endocrine disorder which can result in many severe complications. For patients with hyperparathyroidism, Tc-99m sestamibi imaging is the major imaging tool for pre-operative localization of the hyperfunctioning gland. However, sestamibi scan have only limited sensitivity in detecting multigland disease and hyperplastic foci. New imaging tracer with 18F-fluorocholine (18F-FCH) has showed avidity in parathyroid tissues. Nevertheless, the research data of 18F-FCH PET/CT are only preliminary.
The goal of our study is to compare the diagnostic performance of 18F-FCH PET/CT and single isotope dual phase sestamibi scintigraphy for patients with hyperparathyroidism.
From Jan. 1st, 2018 till Dec. 31st, 2019, the investigators will prospectively enroll patients with biochemical evidence of hyperparathyroidism and intended to receive pre-operative image study. The patients will receive single isotope dual phase sestamibi scintigraphy and 18F-FCH PET/CT. Each image will be evaluated by experienced interpreter for abnormal uptake suspicious for hyperfunctioning parathyroid gland. The reference standard will be the final surgical results. Diagnostic performance of both sestamibi scan and PET/CT scan will be measured and calculated.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators conducted a prospective study to investigate the performance of 18F-choline (FCH) PET/CT and 99mTc- sestamibi scintigraphy in the pre-operative localization of hyperfunctioning parathyroid glands.
Single isotope dual phase Tc-99m sestamibi imaging protocol:
Fasting is not needed before radiotracer injection. No specific drug restriction is needed. Scan will be conduced by using a dual head gamma camera unit (Infinia Hawkeye; GE Medical Systems, Milwaukee,Wis), and scans will be interpreted on a work station with the use of compatible software (Xeleris).
An indwelling intravenous catheter connected to an infusion line and an saline syringe will be set on each patient. 99mTc-sestamibi (925 +/- 10% MBq) will be injected intravenously through the infusion line and will be flushed by saline. The image acquisition of the first phase is to be taken 15 minutes after radiotracer injection. The second phase will be acquired 2-4 hours after the initial tracer injection. The scintigraphic scan field will cover from neck to chest. Additional field-of-view will be performed if the patient has known surgically reimplanted parathyroid gland in the arms.
Two nuclear medicine physicians assess the single isotope dual phase 99mTc-sestamibi scintigraphy. The investigators have access to the patients' history and interpreted individually by each reader, with disagreements to be resolved by consensus. Uptake conspicuity will be evaluated in 4-graded scale. 0. Unable to identify any focal uptake; 1. Inconspicuous focus; 2. Focal mild uptake; 3. Focal intense uptake. For the determination of a diagnosis, score 0 and 1 are considered a negative resulte and 2 to 3 a positive result.
18F-FCH PET imaging protocol: Fasting is not needed before radiotracer injection. No specific drug restriction is needed. Scan will be conduced by using a PET/CT unit (Discovery ST; GE Medical Systems, Milwaukee,Wis), and scans will be interpreted on a work station with the use of compatible software (Xeleris).
An indwelling intravenous catheter connected to an infusion line and an saline syringe will be set on each patient. 18F-FCH (185 +/- 10% MBq) will be injected intravenously through the infusion line and will be flushed by saline. The injected 18F-FCH dose, injection time, post-injection residual activity, time of start imaging and time of end imaging will be recorded on case report form. 18F-FCH PET/CT scan acquisition is to be taken 5 to 10 minutes after radiotracer injection. The PET/CT (80-120 mA, 120 kVp) scan field will cover from skull to mid-thigh. Patient with reimplanted focus will be put into the field-of-view. The 18F-FCH PET/CT scan time will require 35-40 minutes.
Two nuclear medicine physicians assess the 18F-FCH PET/CT images. The investigators have access to the patients' history and interpreted individually by each reader, with disagreements to be resolved by consensus. However, the interpreters have no access to the sestamibi imaging results. For 18F-FCH PET/CT images, uptake conspicuity will be evaluated in 4-graded scale. 0. Unable to identify any focal uptake; 1. Inconspicuous focus; 2. Focal mild uptake; 3. Focal intense uptake. For the determination of a diagnosis, score 0 and 1 are considered a negative resulte and 2 to 3 a positive result.
Reference standard is established by surgical pathology:
The reference standard will be the surgical pathological results. Removed gland will be histologically confirmed as parathyroid adenoma or hyperplasia. For in situ hyperfunctioning parathyroid glands, the image results will be compared with the surgical results as correct lateralization (right side or left side), and correct polarity (upper pole or lower pole), sequentially. For ectopic and reimplanted glands, presence of pathological or biochemical evidence of hyperfunctioning gland removal of the image suggested lesion will be the reference standard.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hualien, Taiwan, 970
- Hualien Tzu Chi Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients are diagnosed to have hyperparathyroidism based on serum iPTH data (> 72 pg/mL).
- Planned to undergo surgical resection of the hyperfunctioning parathyroid gland.
- Referred for single isotope dual phase Tc-99m sestamibi scintigraphy.
- The 18F-FCH PET is performed within 6 weeks of the single isotope dual phase Tc-99m sestamibi scintigraphy.
- If premenopausal and sexually active woman, need contraception (tubal ligation, intrauterine devices, or oral contracepts/condom after the last menstrual period till the image exams)
Exclusion Criteria:
- Surgical management is not considered.
- Younger than 20-year-old.
- Factors that hampers the patient to receive positron emission tomography, e.g., unstable vital signs (shock), conscious disturbance, claustrophobia, etc...
- Allergic to investigaional drug.
- Pregnant or lactating woman.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 18F-fluorocholine PET/CT
|
Patients undergo both 18F-fluorocholine PET/CT and Single isotope dual phase Tc-99m sestamibi scan (both planar scan and SPECT/CT)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The sensitivities of 18F-fluorocholine PET/CT and 99mTc sestamibi scan
Time Frame: 6 weeks
|
The lesion-based sensitivities of these two image modalities using surgical pathology of the parathyroid gland as reference standard (The number of true positive image findings/The number of pathologically confirmed parathyroid adenoma or hyperplasia)
|
6 weeks
|
The specificities of 18F-fluorocholine PET/CT and 99mTc sestamibi scan
Time Frame: 6 weeks
|
The lesion-based specificities of these two image modalities using surgical pathology of the parathyroid gland as reference standard (The number of true negative image findings/The number of negative finding on surgical pathology)
|
6 weeks
|
The accuracies of 18F-fluorocholine PET/CT and 99mTc sestamibi scan
Time Frame: 6 weeks
|
The lesion-based accuracies of these two image modalities using surgical pathology of the parathyroid gland as reference standard (True positive and true negative image findings/The number of all surgical specimens)
|
6 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shu-Hsin Liu, M.D., Hualien Tzu Chi Hospital, Buddhist Tzu ChiMedical Foundation
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB106-74-A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperparathyroidism
-
Postgraduate Institute of Medical Education and...UnknownPrimary Hyperparathyroidism (PHPT)India
-
Nantes University HospitalCompleted
-
Rambam Health Care CampusWithdrawnMultigland Disease in Primary HyperparathyroidismIsrael
-
Nantes University HospitalInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting
-
Brigham and Women's HospitalCompletedPrimary HyperparathyroidismUnited States
-
University Hospital Inselspital, BerneCompletedPrimary HyperparathyroidismSwitzerland
-
EFSTATHIOS CHRONOPOULOSCompletedPrimary Hyperparathyroidism
-
M.D. Anderson Cancer CenterUnknownPrimary HyperparathyroidismUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownPrimary Hyperparathyroidism
-
CHU de ReimsUnknownPrimary HyperparathyroidismFrance
Clinical Trials on 18F-fluorocholine PET/CT
-
Sir Mortimer B. Davis - Jewish General HospitalCompletedProstate CancerCanada
-
Odense University HospitalUniversity of Southern DenmarkUnknown
-
Thomas HopeRecruitingHyperparathyroidism, PrimaryUnited States
-
Poitiers University HospitalCompleted
-
Thomas HopeCompletedHyperparathyroidism, PrimaryUnited States
-
University Medical Centre LjubljanaInstitute of Oncology LjubljanaActive, not recruiting
-
University Health Network, TorontoProstate Cancer CanadaCompleted
-
Sir Mortimer B. Davis - Jewish General HospitalEnrolling by invitation
-
Queen's Medical CenterUnited States Department of DefenseCompletedProstate CancerUnited States
-
Wuxi No. 4 People's HospitalUnknownCarcinoma, Bronchogenic | Lymphoma, Malignant | Breast Carcinoma | Cancer of Head and Neck | Soft Tissue Neoplasms | TumorsChina